Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant carboplatin + nab-paclitaxel in NSCLC with interstitial lung disease
jRCT1041260107Recruiting
- Start
- Aug 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD). Primary endpoint: 2-year disease-free survival rate. Started Aug 2026; status: recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)interstitial lung disease (ILD)
Beyond the preview
Go deeper on jRCT1041260107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041260107.